Analysis of the mechanisms of survival and differentiation inhibition of prostate tumor-propagating cells
| Project/Area Number |
26430177
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Tumor therapeutics
|
|---|
| Research Institution | Japanese Foundation for Cancer Research |
|---|
Principal Investigator |
Mashima Tetsuo 公益財団法人がん研究会, がん化学療法センター 分子生物治療研究部, 主任研究員 (30311228)
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2015: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | がん幹細胞 / 前立腺がん / 小胞体ストレス |
|---|
| Outline of Final Research Achievements |
Prostate cancer has been increasing and has become a major cancer in Japan. Prostate cancer contains highly -tumorigenic ‘cancer stem cells’, which are involved in therapy resistance. So far, however, therapeutic agents targeting the prostate cancer stem cells are not fully identified. In this study, we identified TRIB1 as a novel survival factor for prostate cancer stem cells. TRIB1 supports prostate cancer cell growth via the function of the ER stress protein, GRP78. We also found a candidate compound that suppresses TRIB1-mediated survival signaling. Our findings would be a basis for the development of new therapeutic strategy for complete cure of prostate cancer.
|
Report
(4 results)
Research Products
(17 results)
-
-
[Journal Article] APC mutations as a predictive biomarker for sensitivity to tankyrase inhibitors in colorectal cancer.2017
Author(s)
Noritaka Tanaka, Tetsuo Mashima, Anna Mizutani, Ayana Sato, Aki Aoyama, Bo Gong, Haruka Yoshida, Yukiko Muramatsu, Kento Nakata, Masaaki Matsuura, Ryohei Katayama, Satoshi Nagayama, Naoya Fujita, Yoshikazu Sugimoto, Hiroyuki Seimiya
-
Journal Title
Mol. Cancer Ther.
Volume: 16
Issue: 4
Pages: 739-751
DOI
Related Report
Peer Reviewed / Open Access
-
-
[Journal Article] Serum VEGF-A and CCL5 levels as candidate biomarkers for efficacy and toxicity of regorafenib in patients with metastatic colorectal cancer.2016
Author(s)
Suenaga M, Mashima T, Kawata N, Wakatsuki T, Horiike Y, Matsusaka S, Dan S, Shinozaki E, Seimiya H, Mizunuma N, Yamaguchi K, Yamaguchi T.
-
Journal Title
Oncotarget.
Volume: 7(23)
Issue: 23
Pages: 34811-34823
DOI
Related Report
Peer Reviewed / Open Access / Acknowledgement Compliant
-
[Journal Article] Comprehensive transcriptomic analysis of molecularly targeted drugs in cancer for target pathway evaluation2015
Author(s)
Mashima T, Ushijima M, Matsuura M, Tsukahara S, Kunimasa K, Furuno A, Saito S, Kitamura M, Soma-Nagae T, Seimiya H, Dan S, Yamori T, Tomida A
-
Journal Title
Cancer Science
Volume: in press
Issue: 7
Pages: 909-920
DOI
Related Report
Peer Reviewed / Open Access
-
-
-
-
-
-
-
-
-
-
-
-
